Australia markets closed
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • AUD/USD

    0.7187
    -0.0041 (-0.56%)
     
  • OIL

    84.83
    -0.72 (-0.84%)
     
  • GOLD

    1,836.10
    -6.50 (-0.35%)
     
  • BTC-AUD

    49,469.41
    -4,614.96 (-8.53%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • AUD/EUR

    0.6333
    -0.0054 (-0.85%)
     
  • AUD/NZD

    1.0702
    +0.0008 (+0.07%)
     
  • NZX 50

    12,348.00
    -149.10 (-1.19%)
     
  • NASDAQ

    14,438.40
    -408.06 (-2.75%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • Dow Jones

    34,265.37
    -450.02 (-1.30%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     

Apoptosis Regulator BAX Drugs Development Market Research Report 2021 - ResearchAndMarkets.com

·4-min read

DUBLIN, July 15, 2021--(BUSINESS WIRE)--The "Apoptosis Regulator BAX - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 8 molecules.

Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Ophthalmology which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Hepatocellular Carcinoma, Melanoma, Myocardial Infarction and Parkinson's Disease.

The latest report Apoptosis Regulator BAX - Drugs In Development, 2021, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)

  • The report reviews Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics

Key Topics Covered:

Introduction

  • Report Coverage

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Overview

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Development

  • Products under Development by Stage of Development

  • Products under Development by Therapy Area

  • Products under Development by Indication

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Assessment

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Companies Involved in Therapeutics Development

  • Genervon Biopharmaceuticals LLC

  • Lytix Biopharma AS

  • PHD Biosciences

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Drug Profiles

CYD-211 - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

GM-6 - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

LTX-401 - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Small Molecule to Activate BAX for Acute Myelocytic Leukemia - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Small Molecule to Inhibit BAX for Myocardial Infarction - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Small Molecules to Inhibit BAX for Ophthalmology - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

SMBA-1 - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Dormant Products

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Product Development Milestones

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/eqpojn

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005781/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting